FDA approves carfilzomib and daratumumab with dexamethasone for multiple myeloma

On August 20, 2020, the Food and Drug Administration approved carfilzomib (KYPROLIS, Onyx Pharmaceuticals, Inc.) and daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines o

Source: FDA Center for Drug Evaluation and Research - What's New - August 21, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news